Lytix Biopharma ASA (OSL:LYTIX)

Lytix Biopharma ASA Ratios and Metrics

Market cap in millions NOK. Fiscal year is January - December.

Fiscal Year	Current	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Period Ending	Apr 29, 2026	Dec 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021
Market Capitalization	792	674	401	195	311	533
Market Cap Growth	131.14%	68.03%	106.12%	-37.37%	-41.63%	-
Enterprise Value	722	587	361	116	139	323
Last Close Price	10.30	9.83	5.85	4.84	7.72	13.69
PS Ratio	-	-	36.05	48.79	28.19	27.59
PB Ratio	12.83	10.92	3.72	3.80	2.30	2.81
P/TBV Ratio	12.83	10.92	3.72	3.80	2.30	2.81
EV/Sales Ratio	-	-	32.39	29.06	12.63	16.76
Debt / Equity Ratio	0.04	0.04	0.02	0.01	0.01	0.01
Net Debt / Equity Ratio	-1.14	-1.14	-1.19	-0.97	-1.06	-1.03
Net Debt / EBITDA Ratio	1.10	1.10	1.34	0.52	2.19	4.11
Net Debt / FCF Ratio	1.17	1.17	1.82	0.52	2.73	4.37
Asset Turnover	-	-	0.11	0.04	0.06	0.16
Quick Ratio	4.23	4.23	3.90	5.01	8.51	14.29
Current Ratio	4.28	4.28	3.91	5.06	8.55	14.33
Return on Equity (ROE)	-70.71%	-70.71%	-118.41%	-94.33%	-34.54%	-45.90%
Return on Assets (ROA)	-35.09%	-35.09%	-56.97%	-55.72%	-22.90%	-25.23%
Return on Capital Employed (ROCE)	-101.70%	-101.70%	-87.40%	-188.40%	-48.50%	-25.10%
Earnings Yield	-7.57%	-8.89%	-23.48%	-45.14%	-18.03%	-9.03%
FCF Yield	-	-8.87%	-17.53%	-49.31%	-16.98%	-8.37%
Buyback Yield / Dilution	-26.05%	-26.05%	-35.05%	-1.01%	-19.50%	-26.57%

Source: S&P Global Market Intelligence. Standard template. Financial Sources.